Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Vandetanib

First Posted Date: 2008-05-21

Last Posted Date: 2016-08-29

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT00681798

Locations: 🇨🇭
Research Site, Bellinzona, Switzerland

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin Sodium
Drug: Enoxaparin sodium
Drug: Placebo

First Posted Date: 2008-05-19

Last Posted Date: 2013-12-16

Lead Sponsor: Sanofi

Target Recruit Count: 4413

Registration Number: NCT00679588

Locations: 🇺🇸
Investigational Site Number 840036, Springfield, Illinois, United States
🇺🇸
Investigational Site Number 840007, Huntingdon Beach, California, United States
🇺🇸
Investigational Site Number 840017, Jacksonville, Florida, United States

and more 267 locations

Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties

Phase 3

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: lormetazepam
Drug: eplivanserin (SR46349)

First Posted Date: 2008-05-19

Last Posted Date: 2010-11-30

Lead Sponsor: Sanofi

Target Recruit Count: 283

Registration Number: NCT00679900

Locations: 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain

Lactacyd Radiance (Lactic Acid) Prophetic Patch Test

Phase 2

Completed

Conditions: Hygiene

Interventions: Other: Distilled water
Drug: Lactic Acid

First Posted Date: 2008-05-19

Last Posted Date: 2009-02-06

Lead Sponsor: Sanofi

Target Recruit Count: 200

Registration Number: NCT00679562

Locations: 🇹🇭
Sanofi-Aventis Administrative Office, Bangkok, Thailand

Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Drug: Thiocolchicoside+Ketoprofen
Drug: Thiocolchicoside

First Posted Date: 2008-05-16

Last Posted Date: 2010-06-11

Lead Sponsor: Sanofi

Target Recruit Count: 334

Registration Number: NCT00679146

Locations: 🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

Phase 3

Terminated

Conditions: Obesity
Weight Loss

Interventions: Drug: rimonabant (SR141716)

First Posted Date: 2008-05-15

Last Posted Date: 2009-06-17

Lead Sponsor: Sanofi

Target Recruit Count: 331

Registration Number: NCT00678483

Locations: 🇭🇺
Sanofi- Aventis Administrative Office, Budapest, Hungary
🇷🇴
Sanofi-Aventis Administrative Office, Bucuresti, Romania

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cancer
Advanced Epithelial Ovarian Cancer

Interventions: Drug: Iniparib

First Posted Date: 2008-05-13

Last Posted Date: 2013-10-01

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT00677079

Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: irbesartan/hydrochlorothiazide

First Posted Date: 2008-05-02

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 503

Registration Number: NCT00670566

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Phase 3

Terminated

Conditions: AMI

Interventions: Drug: Insulin Glargine (LANTUS)
Drug: Standard Therapy
Drug: Insulin Glulisine (Apidra)

First Posted Date: 2008-05-01

Last Posted Date: 2011-02-11

Lead Sponsor: Sanofi

Target Recruit Count: 34

Registration Number: NCT00670228

Locations: 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico

Dermacyd Delicata Breeze - Photo Evaluation

Phase 3

Completed

Conditions: Healthy

First Posted Date: 2008-04-29

Last Posted Date: 2009-02-10

Lead Sponsor: Sanofi

Target Recruit Count: 28

Registration Number: NCT00668486

Locations: 🇧🇷
Sanofi-aventis administrative office, São Paulo, Brazil

Home Terms & Conditions Privacy Policy